REFERENCES


Gene Name Pubmed ID Classification Sample Location Remark
MGMT 11297252MethylationParkland Health and Hospital System, Dallas, Texas.MGMT is methylated at relatively high frquencies in high grade CIN and in invasie carcinoma (26-29%), although methylation is lower in the nondysplasia/low grade CIN group. Also methylation of MGMT, which modulates response to cytotoxic agents, may play an important role in cervical cancer.  
MGMT 17971771MethylationVU University Medical Center in AmerstdamMGMT is the most frequently methylated in both tumour histotypes, that is in 92% in all carcinomas.  
MGMT 14760078MethylationDepartment of Obsterics and Gynecology, Innsbruck University Hospital.Aberrant methylation of CpG island within the promoter regions.  
MGMT 19513524MethylationColposcopy Unit of University Hospital of Larissa; Greece.MGMT promoter methylation is found in 13.3% of normal cases, 28.2% of premalignant cases and 72.5% of cancer cases.  
MGMT 11448914Methylation-Aberrant methylation of CpG island within the promoter regions.  
MGMT 19836067MethylationChonnam National University Hwasun HospitalThe trend of methylation of this gene is increasing with increasing severity of cervical squamous lesions (p<0.001).  
MGMT 15589597MethylationDepartment of Obstertics and Gynecology, Seoul national University Hospital.Frequency of methylation of this gene is found to be 19.5%.  
MGMT 15785933MethylationDepartment of pathology, Anam Hospital of Korea UniversityNone of 20 non-neoplastic cervices showed p16 INK4A and MGMT gene hypermethylation, whereas at least one of these genes was hypermethylated with 50.0% (5/10) of CIN I, 65.0% (13/20) of CIN II-III, 70.2% (33/47) of SCC and 85.0% (17/20) of adenocarcinoma  
MGMT 16928264Methylation-Incidence of hypermethylation for DAPK, MGMT, p16 and PTEN in cervical cancer was 56.7%, 25.2%, 16.5% and 15.7% respectively  
MGMT 15099958MethylationQueen Mary Hospital, Hong Kong.Promotor CpG island methylation of DAPK, p16, and MGMT was detectable, respectively, in 60%, 28.2%, and 18.8% of cases of cervical tumor DNA, and in 40%, 10%, and 7.5% of cases of patients' plasma DNA  
MGMT 15713962Methylation-hypermethylation rates were twice as high among samples from women with confirmed ICC as the rates among samples from women with CIN-1 or less